MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco-25-00036

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025

Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.

Bradley Jeffrey D, Sugawara Shunichi, Lee Ki Hyeong, Ostoros Gyula, Demirkazik Ahmet, Zemanova Milada, Sriuranpong Virote, Gelatti Ana Caroline Zimmer, de Menezes Juliana Janoski, Zurawski Bogdan, Newton Michael, Chander Pratibha, Jia Nan, Bielecka Zofia F, Özgüroğlu Mustafa, PACIFIC-2 Investigators

СтатьяРандомизированное исследованиеКлиническое исследование III фазыМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

PURPOSE: Immunotherapy targeting PD-L1 improves outcomes in patients with unresectable stage III non-small cell lung cancer (NSCLC) and no progression after definitive, concurrent chemoradiotherapy (cCRT). Earlier administration of immunotherapy, simultaneously with cCRT, may improve outcomes further.

METHODS

Eligible patients were randomly assigned (2:1) to receive either durvalumab or placebo administered from the start of cCRT. Patients without progression after completing cCRT received consolidation durvalumab or placebo (per initial random assignment) until progression. The primary end point was progression-free survival (PFS) by blinded independent central review. Key secondary end points included objective response rate (ORR), overall survival (OS), the proportion of patients alive at 24 months (OS24), and safety.

RESULTS

In total, 328 patients were randomly assigned to receive durvalumab (n = 219) or placebo (n = 109). There was no statistically significant difference with durvalumab versus placebo in PFS (hazard ratio [HR], 0.85 [95% CI, 0.65 to 1.12]; P = .247) or OS (HR, 1.03 [95% CI, 0.78 to 1.39]; P = .823); OS24 was 58.4% versus 59.5%, respectively. Confirmed ORR was 60.7% with durvalumab versus 60.6% with placebo (difference, 0.2% [95% CI, -15.2 to 16.3%]; P = .976). With durvalumab versus placebo, respectively, maximum grade 3 or 4 adverse events (AEs) occurred in 53.4% versus 59.3% of patients, pneumonitis or radiation pneumonitis (group term) in 28.8% (grade ≥3: 4.6%) versus 28.7% (grade ≥3: 5.6%), AEs leading to discontinuation of durvalumab or placebo in 25.6% versus 12.0%, and fatal AEs in 13.7% versus 10.2%.

CONCLUSION

Among patients with unresectable stage III NSCLC, durvalumab administered from the start of cCRT failed to demonstrate additional benefit compared with cCRT plus placebo. Consolidation durvalumab following definitive cCRT remains the standard of care in this setting.

Для цитирования: Bradley Jeffrey D, Sugawara Shunichi, Lee Ki Hyeong, Ostoros Gyula, Demirkazik Ahmet, Zemanova Milada, Sriuranpong Virote, Gelatti Ana Caroline Zimmer, de Menezes Juliana Janoski, Zurawski Bogdan, Newton Michael, Chander Pratibha, Jia Nan, Bielecka Zofia F, Özgüroğlu Mustafa, PACIFIC-2 Investigators. Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. DOI: 10.1200/jco-25-00036.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.